Holen Sie sich die Stockscreener-App
77.05
3.75%
-3.275
Schlusskurs vom Vortag:
$80.32
Offen:
$80.45
24-Stunden-Volumen:
894.78K
Relative Volume:
0.98
Marktkapitalisierung:
$3.33B
Einnahmen:
$2.04M
Nettoeinkommen (Verlust:
$-162.34M
KGV:
-18.73
EPS:
-4.1129
Netto-Cashflow:
$-129.27M
1W Leistung:
+18.57%
1M Leistung:
+63.10%
6M Leistung:
+108.05%
1J Leistung:
+263.30%
1-Tages-Spanne:
$76.22
$82.27
1-Wochen-Bereich:
$76.07
$88.02
52-Wochen-Spanne:
$13.37
$88.02
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Firmenname
Dianthus Therapeutics Inc
Sektor
Branche
Telefon
929-999-4055
Adresse
7 TIMES SQUARE, NEW YORK
Compare DNTH vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
77.05 | 3.47B | 2.04M | -162.34M | -129.27M | -4.1129 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.38 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.36 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
704.47 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.33 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.43 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-14 | Eingeleitet | Truist | Buy |
| 2025-07-02 | Eingeleitet | William Blair | Outperform |
| 2024-12-20 | Eingeleitet | TD Cowen | Buy |
| 2024-10-03 | Eingeleitet | Oppenheimer | Outperform |
| 2024-07-26 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-06-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-05-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-02-15 | Eingeleitet | Stifel | Buy |
| 2023-12-26 | Eingeleitet | Jefferies | Buy |
| 2023-11-22 | Eingeleitet | Wedbush | Outperform |
| 2023-10-30 | Eingeleitet | Guggenheim | Buy |
| 2023-09-28 | Eingeleitet | Raymond James | Outperform |
| 2022-08-25 | Herabstufung | Goldman | Buy → Neutral |
| 2022-01-06 | Hochstufung | Goldman | Neutral → Buy |
| 2021-08-20 | Fortgesetzt | Goldman | Neutral |
| 2021-08-03 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-22 | Bestätigt | B. Riley Securities | Buy |
| 2021-06-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-18 | Eingeleitet | B. Riley Securities | Buy |
| 2021-01-07 | Eingeleitet | Mizuho | Buy |
| 2020-06-08 | Hochstufung | Goldman | Neutral → Buy |
| 2019-03-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-03-15 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Dianthus Therapeutics Inc Aktie (DNTH) Neueste Nachrichten
Dianthus Therapeutics (DNTH) Is Up 30.8% After Upsized Raise And Early Phase 3 “Go” Decision - Yahoo Finance
Dianthus Therapeutics closes $719M public offering - Investing.com
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - Bitget
Biotech Dianthus raises $719M to push autoimmune disease drugs - Stock Titan
Dianthus Therapeutics Launches $81-Per-Share Offering; Net Proceeds Expected at $673.5 Million - TradingView
Dianthus Therapeutics Announces Major Public Equity Offering - TipRanks
Q1 EPS Estimate for Dianthus Therapeutics Reduced by Analyst - MarketBeat
Midtown drug company to sell up to $625M in stock to fund autoimmune research - Crain's New York
Best Biotech Stocks To ConsiderMarch 11th - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Sees Strong Trading Volume After Analyst Upgrade - MarketBeat
Biotech Dianthus prices $625M deal to advance autoimmune drugs - Stock Titan
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering - Bitget
Dianthus Therapeutics shares jump 25% after encouraging clinical trial update - MSN
Dianthus Therapeutics says co. prices upsized offering of 7,313,582 shares at $81.00 per share - marketscreener.com
Dianthus Therapeutics Announces Pricing of $625 Million Upsized Public Offering of Common Stock - Quiver Quantitative
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering - GlobeNewswire Inc.
Dianthus Therapeutics’ CAPTIVATE Trial Sparks Renewed Investor Interest - timothysykes.com
Surge in Dianthus Therapeutics Stock Amid Positive Trial Results - StocksToTrade
DNTH Stock Jumps 21.5% Despite Wider-Than-Expected Q4 Loss as Pipeline Prospects Fuel Rally - AlphaStreet
Dianthus Therapeutics: Go Decision For CIDP Program Warrants Continued Buy Rating (DNTH) - Seeking Alpha
AutoZone To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Dianthus Therapeutics (NASDAQ:DNTH) Raised to Strong-Buy at Raymond James Financial - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Price Target Raised to $80.00 - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Expected to Rise, Robert W. Baird Analyst Says - MarketBeat
Guggenheim Reiterates Buy Rating for Dianthus Therapeutics (DNTH) - Finviz
Investment firm Raymond James announced an upgrade of biopharmaceutical company Dianthus Therapeutics Inc. (DNTH) stock rating from "Outperform" to "Strong Buy". - Bitget
Beyond the Balance Sheet: What SWOT Reveals About Dianthus Thera - GuruFocus
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds - Insider Monkey
Dianthus Therapeutics Hits New 1-Year High After Analyst Upgrade - National Today
AI Integration Exposes Dianthus Therapeutics to Heightened Cyber, Privacy, and Reputational Risks - TipRanks
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 1-Year High Following Analyst Upgrade - MarketBeat
Dianthus Therapeutics launches $400M stock offering - Investing.com Nigeria
Cowen Maintains Buy on DNTH and Oppenheimer Keeps Outperform March 2026 - Meyka
Clear Street raises Dianthus Therapeutics price target on CIDP trial data - Investing.com Canada
Guggenheim’s Bold Move: Price Target for Dianthus Doubles to $200 - timothysykes.com
Dianthus Therapeutics announces proposed $400 million underwritten public offering - marketscreener.com
Dianthus Therapeutics Announces Proposed $400 Million Underwritten Public Offering - TradingView
Dianthus Therapeutics announces proposed $400 million public share offering - MSN
Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering - Bitget
Dianthus Therapeutics shares fall 5% after announcing $400 million stock offering - Investing.com Canada
Jefferies raises Dianthus Therapeutics stock price target on CIDP trial progress - Investing.com Canada
Dianthus Therapeutics launches $400M stock offering By Investing.com - Investing.com Canada
Dianthus Therapeutics stock rallies—rare disease study success fuels optimism - MSN
Dianthus plans $400M share sale to fund autoimmune drug trials - Stock Titan
Biotech Stocks To Add to Your WatchlistMarch 9th - MarketBeat
Dianthus Therapeutics Reports 2025 Financial Results and Advancements in Claseprubart Phase 3 Trials for Autoimmune Diseases - Minichart
Guggenheim Boosts Price Target for Dianthus as Sales Projections Soar - StocksToTrade
DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch - Asianet Newsable
HC Wainwright Increases Dianthus Therapeutics (NASDAQ:DNTH) Price Target to $130.00 - MarketBeat
Guggenheim Doubles Price Target for Dianthus: A Promising Future? - timothysykes.com
Finanzdaten der Dianthus Therapeutics Inc-Aktie (DNTH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):